Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin in Staged Non-IRA Intervention for STEMI
NCT04475835Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bivalirudin in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Net adverse clinical events at 30 days. Status: unknown.
02
Drugs
bivalirudin
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT04475835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04475835.